Compare SNDX & MAN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SNDX | MAN |
|---|---|---|
| Founded | 2005 | 1948 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Professional Services |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6B | 1.4B |
| IPO Year | 2014 | 1994 |
| Metric | SNDX | MAN |
|---|---|---|
| Price | $21.31 | $36.20 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 13 | 6 |
| Target Price | ★ $38.69 | $35.67 |
| AVG Volume (30 Days) | ★ 1.8M | 812.8K |
| Earning Date | 04-30-2026 | 04-16-2026 |
| Dividend Yield | N/A | ★ 4.69% |
| EPS Growth | ★ 11.56 | N/A |
| EPS | N/A | ★ 0.05 |
| Revenue | $172,352,000.00 | ★ $17,957,100,000.00 |
| Revenue This Year | $107.19 | $5.12 |
| Revenue Next Year | $41.88 | $3.42 |
| P/E Ratio | ★ N/A | $676.20 |
| Revenue Growth | ★ 627.84 | 0.58 |
| 52 Week Low | $8.59 | $25.15 |
| 52 Week High | $25.59 | $47.34 |
| Indicator | SNDX | MAN |
|---|---|---|
| Relative Strength Index (RSI) | 64.08 | 66.15 |
| Support Level | $19.28 | $28.29 |
| Resistance Level | $22.40 | $36.87 |
| Average True Range (ATR) | 0.79 | 1.57 |
| MACD | 0.37 | 0.06 |
| Stochastic Oscillator | 96.81 | 77.05 |
Syndax Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. Its product candidates include revumenib and axatilimab. It is developing revumenib, a selective menin-MLL inhibitor for KMT2A-rearranged (MLL-r) and NPM1-mutant acute leukemias, including ALL and AML. It is also developing axatilimab, a CSF-1R-blocking antibody for cGVHD and idiopathic pulmonary fibrosis. Entinostat is its oral, small molecule product candidate that has direct effects on both cancer cells and immune regulatory cells. The business activity of the group is functioned through the region of the United States.
ManpowerGroup Inc provides workforce solutions and services, including recruitment and assessment, upskilling, reskilling, training and development, career management, outsourcing, and workforce consulting. The company leverages its trusted brands, industry knowledge, and AI-enabled assessments and offers an extensive portfolio of training and leadership development solutions. Its reportable segments are Staffing and Interim, Outcome-Based Solutions and Consulting, Permanent Recruitment, and Others, with Staffing and Interim generating the majority of revenue. It operates in the Americas, Southern Europe, Northern Europe, and APME. The company derives the maximum geographical revenue from the Southern European region.